Travere Therapeutics Inc (TVTX)

$9.84

+0.07

(+0.72%)▲

Live

Performance

  • $9.69
    $10.06
    $9.84
    downward going graph

    1.52%

    Downside

    Day's Volatility :3.68%

    Upside

    2.19%

    downward going graph
  • $5.12
    $17.57
    $9.84
    downward going graph

    47.97%

    Downside

    52 Weeks Volatility :70.86%

    Upside

    44.0%

    downward going graph

Returns

PeriodTravere Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
85.74%
6.5%
0.0%
6 Months
13.6%
7.1%
0.0%
1 Year
-40.21%
9.8%
0.0%
3 Years
-27.58%
14.2%
-20.2%

Highlights

Market Capitalization
759.0M
Book Value
$0.97
Earnings Per Share (EPS)
-5.41
Wall Street Target Price
14.86
Profit Margin
-103.47%
Operating Margin TTM
-335.91%
Return On Assets TTM
-35.53%
Return On Equity TTM
-315.89%
Revenue TTM
155.7M
Revenue Per Share TTM
2.04
Quarterly Revenue Growth YOY
33.900000000000006%
Gross Profit TTM
-31.4M
EBITDA
-376.6M
Diluted Eps TTM
-5.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.69
EPS Estimate Next Year
-1.55
EPS Estimate Current Quarter
-0.99
EPS Estimate Next Quarter
-0.8

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Travere Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
17
Hold
6
6
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 51.02%

Current $9.84
Target $14.86

Company Financials

FY18Y/Y Change
Revenue
164.2M
↑ 6.01%
Net Income
-102.7M
↑ 71.9%
Net Profit Margin
-62.51%
↓ 23.96%
FY19Y/Y Change
Revenue
175.3M
↑ 6.75%
Net Income
-146.4M
↑ 42.61%
Net Profit Margin
-83.51%
↓ 21.0%
FY20Y/Y Change
Revenue
198.3M
↑ 13.11%
Net Income
-169.4M
↑ 15.71%
Net Profit Margin
-85.43%
↓ 1.92%
FY21Y/Y Change
Revenue
227.5M
↑ 14.71%
Net Income
-180.1M
↑ 6.29%
Net Profit Margin
-79.16%
↑ 6.27%
FY22Y/Y Change
Revenue
212.0M
↓ 6.8%
Net Income
-278.5M
↑ 54.63%
Net Profit Margin
-131.35%
↓ 52.19%
FY23Y/Y Change
Revenue
145.2M
↓ 31.5%
Net Income
-111.4M
↓ 60.0%
Net Profit Margin
-76.7%
↑ 54.65%
Q4 FY22Q/Q Change
Revenue
55.9M
↑ 4.43%
Net Income
-65.8M
↓ 5.5%
Net Profit Margin
-117.82%
↑ 12.39%
Q1 FY23Q/Q Change
Revenue
57.0M
↑ 2.01%
Net Income
-86.3M
↑ 31.16%
Net Profit Margin
-151.48%
↓ 33.66%
Q2 FY23Q/Q Change
Revenue
59.7M
↑ 4.74%
Net Income
-85.6M
↓ 0.81%
Net Profit Margin
-143.44%
↑ 8.04%
Q3 FY23Q/Q Change
Revenue
37.1M
↓ 37.86%
Net Income
150.7M
↓ 276.03%
Net Profit Margin
406.35%
↑ 549.79%
Q4 FY23Q/Q Change
Revenue
45.1M
↑ 21.47%
Net Income
-90.2M
↓ 159.82%
Net Profit Margin
-200.12%
↓ 606.47%
Q1 FY24Q/Q Change
Revenue
41.4M
↓ 8.18%
Net Income
-136.1M
↑ 50.89%
Net Profit Margin
-328.86%
↓ 128.74%
FY18Y/Y Change
Total Assets
709.2M
↑ 36.29%
Total Liabilities
390.9M
↑ 72.05%
FY19Y/Y Change
Total Assets
604.8M
↓ 14.72%
Total Liabilities
383.6M
↓ 1.87%
FY20Y/Y Change
Total Assets
607.4M
↑ 0.44%
Total Liabilities
396.2M
↑ 3.29%
FY21Y/Y Change
Total Assets
776.6M
↑ 27.85%
Total Liabilities
474.5M
↑ 19.76%
FY22Y/Y Change
Total Assets
672.6M
↓ 13.4%
Total Liabilities
629.7M
↑ 32.71%
FY23Y/Y Change
Total Assets
788.9M
↑ 17.3%
Total Liabilities
588.1M
↓ 6.61%
Q4 FY22Q/Q Change
Total Assets
672.6M
↓ 7.38%
Total Liabilities
629.7M
↑ 0.67%
Q1 FY23Q/Q Change
Total Assets
808.2M
↑ 20.17%
Total Liabilities
619.1M
↓ 1.69%
Q2 FY23Q/Q Change
Total Assets
736.4M
↓ 8.88%
Total Liabilities
619.9M
↑ 0.14%
Q3 FY23Q/Q Change
Total Assets
832.9M
↑ 13.09%
Total Liabilities
553.1M
↓ 10.78%
Q4 FY23Q/Q Change
Total Assets
788.9M
↓ 5.28%
Total Liabilities
588.1M
↑ 6.33%
Q1 FY24Q/Q Change
Total Assets
663.5M
↓ 15.89%
Total Liabilities
589.5M
↑ 0.23%
FY18Y/Y Change
Operating Cash Flow
-25.0M
↓ 437.13%
Investing Cash Flow
-203.3M
↓ 545.79%
Financing Cash Flow
231.9M
↑ 4158.27%
FY19Y/Y Change
Operating Cash Flow
-58.2M
↑ 133.25%
Investing Cash Flow
19.9M
↓ 109.77%
Financing Cash Flow
-2.1M
↓ 100.9%
FY20Y/Y Change
Operating Cash Flow
-42.7M
↓ 26.58%
Investing Cash Flow
-61.3M
↓ 408.75%
Financing Cash Flow
127.7M
↓ 6248.92%
FY21Y/Y Change
Operating Cash Flow
-14.8M
↓ 65.39%
Investing Cash Flow
-137.6M
↑ 124.41%
Financing Cash Flow
231.7M
↑ 81.41%
FY22Y/Y Change
Operating Cash Flow
-186.3M
↑ 1159.4%
Investing Cash Flow
-32.6M
↓ 76.35%
Financing Cash Flow
117.6M
↓ 49.25%
Q4 FY22Q/Q Change
Operating Cash Flow
-54.6M
↑ 38.24%
Investing Cash Flow
-36.7M
↓ 464.13%
Financing Cash Flow
551.0K
↓ 75.81%
Q1 FY23Q/Q Change
Operating Cash Flow
-81.1M
↑ 48.46%
Investing Cash Flow
-37.0M
↑ 0.92%
Financing Cash Flow
217.0M
↑ 39282.21%
Q2 FY23Q/Q Change
Operating Cash Flow
-69.3M
↓ 14.57%
Investing Cash Flow
-23.6M
↓ 36.41%
Financing Cash Flow
2.3M
↓ 98.96%

Technicals Summary

Sell

Neutral

Buy

Travere Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Travere Therapeutics Inc
Travere Therapeutics Inc
18.42%
13.6%
-40.21%
-27.58%
-52.8%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Travere Therapeutics Inc
Travere Therapeutics Inc
NA
NA
NA
-3.69
-3.16
-0.36
NA
0.97
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Travere Therapeutics Inc
Travere Therapeutics Inc
Buy
$759.0M
-52.8%
NA
-103.47%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Travere Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 45.05M → 41.37M (in $), with an average decrease of 8.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 150.73M → -136.06M (in $), with an average decrease of 105.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 101.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 214.1%

Institutional Holdings

  • BlackRock Inc

    10.24%

  • Armistice Capital, LLC

    9.85%

  • Deep Track Capital, LP

    9.68%

  • State Street Corporation

    8.68%

  • Vanguard Group Inc

    8.23%

  • Macquarie Group Ltd

    6.06%

Company Information

Organization
Travere Therapeutics Inc
Employees
380
CEO
Dr. Eric M. Dube Ph.D.
Industry
Health Technology

Discover More

FAQs